Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors

This study has been completed.

Study NCT00054548 Information provided by National Cancer Institute (NCI)

First Received: February 5, 2003 Last Updated: April 4, 2009 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	May 2008 (Final data collection date for primary outcome measure)

Publications:

Liu G, Kolesar J, McNeel DG, Leith C, Schell K, Eickhoff J, Lee F, Traynor A, Marnocha R, Alberti D, Zwiebel J, Wilding G. A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2008 May 1;14(9):2732-2739.

Lalich M, Wilding G, Kolesar J, et al.: A Phase I study of antisense Bcl-2 Oligonucleotide (G3139) in combination with carboplatin (C) and paclitaxel (T) in patients with advanced solid tumors. [Abstract] J Clin Oncol 24 (Suppl 18): A-13006, 602s, 2006.